Nov. 18, 2021—Roche launched its Cobas 5800 system in countries accepting the CE mark.
The real-time PCR molecular testing solution is built to offer a fully automated workflow that encompasses sample supply, transfer and preparation, amplification and detection, result calculation, and delivery to the laboratory information system. The single module enables a walkaway time of up to eight hours.
“Diagnostics continue to revolutionize how providers care for patients, and it is essential, now more than ever, that the health care community has access to reliable and accurate testing solutions,” Thomas Schinecker, CEO Roche Diagnostics, said in a press statement. ”We are pleased that we can now offer a compact, fully-automated molecular system such as the Cobas 5800 System. This new system helps to address the high demands on labs through greater efficiency, optimized workflows, and cost savings, enabling them to deliver quality patient care.”
The Cobas 5800 system will offer the same menu as the Cobas 6800 and 8800 systems, including the Cobas SARS-CoV-2 test. The system offers an expanded onboard capacity allowing labs to test multiple assays simultaneously and delivers up to 144 results in an eight-hour shift.
Roche anticipates receiving FDA approval during the third quarter of 2022.